PMV Pharmaceuticals, Inc., a leader in the discovery and development of p53-targeted small molecule drugs for the treatment of cancer announced the completion of a $74 million Series B financing round.
This financing was led by Topspin Biotech Fund and a group of investors with Euclidean Capital, with participation from existing investors InterWest Partners, OrbiMed Advisors, and Osage University Partners.
The proceeds will be used to develop and advance into the clinic the Company’s pipeline of mutant p53 restoration drug candidates.
p53 is the most commonly mutated protein in human cancers, with more than half of all tumors containing mutant p53. The protein plays a pivotal role in the body’s natural defense mechanism against cancer and induces a highly-organized program of cellular death to prevent the proliferation of potentially cancerous cells.
Cancer cells often have mutations in p53 that enable them to escape death. PMV Pharma’s unique mechanism of action promises to restore p53 to its normal function, eliminating this escape route and selectively killing the mutant cancer cells without affecting normal tissues.
“PMV Pharmaceutical’s world-class founders, scientific advisors, and leadership team, together with its transformative chemistry and biology platform position PMV Pharma to be a leader in next-generation cancer therapies to improve patients’ lives,” said Steve Winick of Topspin. In conjunction with the Series B financing, Mr. Winick will be joining PMV’s Board of Directors.
“This financing provides PMV Pharma with the resources to broadly expand our pipeline and to bring p53 therapies to the clinic,” said David Mack, Ph.D., President and CEO of PMV Pharmaceuticals. “We are excited to have Topspin join us in our pursuit of developing meaningful new medicines for large segments of the cancer population. The enthusiasm and confidence from our new and existing investors underscore the important advances we have made.”
About PMV Pharma
PMV Pharma was co-founded by Dr. Arnold Levine, one of the discoverers of the p53 protein and a professor emeritus at the Simons Center for Systems Biology at the Institute for Advanced Study. p53 is the most commonly mutated gene in cancer, with over 50 percent of all human tumors containing a p53 mutant protein. PMV Pharma is developing first-in-class p53 and p53 pathway modulators for the treatment of cancer. Bringing together leaders in the field to utilize over three decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey.
Contact:
David H. Mack, Ph.D.
President & CEO
PMV Pharmaceuticals, Inc.
dmack@pmvpharma.com
Amiad Finkelthal
Russo Partners
amiad.finkelthal@russopartnersllc.com
(646) 942-5626
(917) 217-1838 mobile
Shai Biran, Ph.D.
Russo Partners
shai.biran@russopartnersllc.com
(212) 845-4253
(917) 915-2416 mobile
